IP Library Granted Patent US 8,754,219
Granted Patent B2
US 8,754,219 · App. 13/643,537 · Granted Jun 17, 2014

Compounds that modulate intracellular calcium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,754,219
App. No.
13/643,537
Granted
Jun 17, 2014
Kind
B2
Abstract

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Claims (25)

1. A compound having the structure of Formula (III) having the structure:

wherein:

R″ 1 is

L 2 is —NH—C(═O)—, or —C(═O)NH—;

R 2 is phenyl or pyridyl; wherein phenyl or pyridyl is optionally substituted with at least one R 3 ;

R 3 is independently selected from F, Cl, Br, I, —CN, —NO 2 , —OH, —OCF 3 , —OR 5 , and —N(R 5 ) 2 ;

n is an integer selected from 1-4;

each R 5 is independently selected from C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;

R 7 is selected from C 1 -C 6 alkyl;

R 6 is selected from F, Cl, Br, I, —CN, —NO 2 , —OH, —CF 3 , —OCF 3 , —OR 5 , C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 1 -C 6 haloalkyl;

or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof.

2. The compound of claim 1 having the structure of Formula (IIIA):

3. The compound of claim 2 wherein L 2 is —NH—C(═O)—.

4. The compound of claim 3 wherein R 2 is phenyl.

5. The compound of claim 4 wherein the phenyl group is substituted with at least one R 3 selected from F, Cl, Br, I, —CN, —OH, —OCF 3 , —OR 5 , and —N(R 5 ) 2 .

6. The compound of claim 5 wherein R 6 is selected from —CF 3 , —OCF 3 , —OR 5 , C 1 -C 6 alkyl, and C 3 -C 8 cycloalkyl.

7. The compound of claim 6 wherein R 6 is —CF 3 and R 7 is —CH 3 .

8. The compound of claim 5 wherein n is 1.

9. The compound of claim 8 wherein R 3 is fluorine.

10. The compound of claim 5 wherein phenyl is substituted with at least 2 F substituents.

11. The compound of claim 5 wherein phenyl is substituted with at least 3 F substituents.

12. The compound of claim 3 wherein R 2 is pyridyl.

13. The compound of claim 12 wherein pyridyl is substituted with at least one R 3 selected from F, Cl, Br, —OH, —CN, —OCF 3 , —OR 5 , and —N(R 5 ) 2 .

14. The compound of claim 13 wherein pyridyl is substituted with at least one fluorine.

15. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient or binder, and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (2)
SECURITY INTEREST Recorded Mar 4, 2025
From: CALCIMEDICA, INC.
To: AVENUE CAPITAL MANAGEMENT II, L.P.
Reel/Frame 070394/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2013
From: WHITTEN, JEFFREY P.; PEI, YAZHONG; CAO, JIANGUO; WANG, ZHIJUN; ROGERS, EVAN; DYCK, BRIAN; GREY, JONATHAN
To: CALCIMEDICA, INC.
Reel/Frame 030557/0770 →